Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer - Takeaways - MDSpire

Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer

  • By

  • José P. Leone

  • Julieta Leone

  • Pietro De Placido

  • Faina Nakhlis

  • Ilana Schlam

  • Kelly A. Hirko

  • Aditi Hazra

  • Elizabeth Troll

  • Jennifer R. Bellon

  • Carlos T. Vallejo

  • Nancy U. Lin

  • Sara M. Tolaney

  • Filipa Lynce

  • April 9, 2026

  • 0 min

Share

  • 1

    Inflammatory breast cancer (IBC) is a rare, aggressive cancer with poorer outcomes compared to non-inflammatory breast cancer (non-IBC).

  • 2

    Trimodality therapy (TMT) is the standard treatment for IBC, involving neoadjuvant therapy, mastectomy, and postmastectomy radiotherapy.

  • 3

    Treatment de-escalation has not proven safe for IBC, unlike non-IBC, where it has led to successful outcomes.

  • 4

    The study analyzed 47,702 patients, with 6.8% diagnosed with IBC, revealing significant demographic and tumor characteristic differences.

  • 5

    Breast cancer-specific survival (BCSS) and overall survival (OS) were evaluated, highlighting disparities between IBC and non-IBC outcomes.

Original Source(s)

Outcomes and Treatment Approaches for Stage III Inflammatory versus Noninflammatory Breast Cancer

  • by José P. Leone, Julieta Leone, Pietro De Placido, Faina Nakhlis, Ilana Schlam, Kelly A. Hirko, Aditi Hazra, Elizabeth Troll, Jennifer R. Bellon, Carlos T. Vallejo, Nancy U. Lin, Sara M. Tolaney, Filipa Lynce

  • April 9, 2026

Related Content

Longitudinal predictor analysis of pain in breast cancer survivors on aromatase inhibitors—the PAC-WOMAN trial

Combined reconstruction of complex chest wall defects using mesh-supported rigid materials and abdominal flap strategies: a retrospective clinical study

Successful reversal of hepatic visceral crisis in HER2-positive metastatic breast cancer: a case report